Callidus Capital Corporation announced effective immediately, Newton Glassman, Callidus' Executive Chairman and Chief Executive Officer, will take a medical leave of absence. Mr. Glassman is currently undergoing further medical tests and examinations to confirm the extent and seriousness of his conditions. In connection with Mr. Glassman's immediate leave of absence, the Callidus Board of Directors has re-assigned Mr. Glassman's CEO responsibilities to the existing Callidus management team.

Further, Mr. Glassman intends to remain as Executive Chair and a Director of Callidus. He has also committed to remain Chair of the Callidus Credit Committee. To the extent deemed necessary in the future by Callidus, Catalyst will provide personnel and/or resources necessary to ensure all of Mr. Glassman's functions at Callidus are fulfilled as seamlessly and efficiently as possible.

Mr. Glassman will remain in his role of Managing Partner of The Catalyst Capital Group Inc.